D N (Israel) Performance

DNA -- Israel Stock  

ILS 26.50  0.10  0.38%

D N has performance score of 2 on a scale of 0 to 100. The corporation shows Beta (market volatility) of 0.0718 which denotes to the fact that as returns on market increase, D N returns are expected to increase less than the market. However during bear market, the loss on holding D N will be expected to be smaller as well. Although it is extremely important to respect D N A historical returns, it is better to be realistic regarding the information on equity current trending patterns. The approach into predicting future performance of any stock is to evaluate the business as a whole together with its past performance including all available fundamental and technical indicators. By analyzing D N A technical indicators you can at this moment evaluate if the expected return of 0.0799% will be sustainable into the future. D N A today shows a risk of 2.3713%. Please confirm D N A Maximum Drawdown, and the relationship between Information Ratio and Downside Variance to decide if D N A will be following its price patterns.
2

Risk-Adjusted Performance

Compared to the overall equity markets, risk-adjusted returns on investments in D N A Biomedical Solutions Ltd are ranked lower than 2 (%) of all global equities and portfolios over the last 30 days. Despite somewhat strong basic indicators, D N is not utilizing all of its potentials. The current stock price disturbance, may contribute to short term losses for the investors.
Quick Ratio0.03
Fifty Two Week Low20.70
Fifty Two Week High32.90
Horizon     30 Days    Login   to change

D N A Relative Risk vs. Return Landscape

If you would invest  2,610  in D N A Biomedical Solutions Ltd on March 21, 2019 and sell it today you would earn a total of  40.00  from holding D N A Biomedical Solutions Ltd or generate 1.53% return on investment over 30 days. D N A Biomedical Solutions Ltd is generating 0.0799% of daily returns assuming 2.3713% volatility of returns over the 30 days investment horizon. Simply put, 21% of all equities have less volatile historical return distribution than D N and 99% of equity instruments are likely to generate higher returns than the company over the next 30 trading days.
 Daily Expected Return (%) 
      Risk (%) 
Assuming 30 trading days horizon, D N is expected to generate 4.14 times more return on investment than the market. However, the company is 4.14 times more volatile than its market benchmark. It trades about 0.03 of its potential returns per unit of risk. The DOW is currently generating roughly 0.12 per unit of risk.

D N Market Risk Analysis

Sharpe Ratio = 0.0337
Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
DNAHigh
Risk
Huge
Risk
Negative Returns

D N Relative Performance Indicators

Estimated Market Risk
 2.37
  actual daily
 
 21 %
of total potential
 
21
Expected Return
 0.08
  actual daily
 
 1 %
of total potential
 
1
Risk-Adjusted Return
 0.03
  actual daily
 
 2 %
of total potential
 
2
Based on monthly moving average D N is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of D N by adding it to a well-diversified portfolio.

D N Alerts

Equity Alerts and Improvement Suggestions

D N A has high likelihood to experience some financial distress in the next 2 years
The company has accumulated zero balance in total debt. D N A has Current Ratio of 0.03 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.
The entity reported revenue of . Net Loss for the year was (14.29M).
DNA BIOMED SOLUT has accumulated about 492K in cash with (1.66M) of positive cash flow from operations.
Additionally see Investing Opportunities. Please also try Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Search macroaxis.com